HOTH THERAPEUTICS INC (HOTH) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:HOTH • US44148G2049

0.95 USD
+0.09 (+10.68%)
At close: Feb 10, 2026
0.905 USD
-0.04 (-4.74%)
After Hours: 2/10/2026, 8:12:49 PM

HOTH Key Statistics, Chart & Performance

Key Statistics
Market Cap14.73M
Revenue(TTM)N/A
Net Income(TTM)-12.16M
Shares15.51M
Float14.96M
52 Week High2.12
52 Week Low0.66
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-1.06
PEN/A
Fwd PEN/A
Earnings (Next)03-26
IPO2019-02-15
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
HOTH short term performance overview.The bars show the price performance of HOTH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

HOTH long term performance overview.The bars show the price performance of HOTH in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of HOTH is 0.95 USD. In the past month the price decreased by -10.38%. In the past year, price decreased by -15.93%.

HOTH THERAPEUTICS INC / HOTH Daily stock chart

HOTH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HOTH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HOTH. HOTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HOTH Financial Highlights

Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -131.58%
ROE -147.77%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%3.23%
Sales Q2Q%N/A
EPS 1Y (TTM)20.3%
Revenue 1Y (TTM)N/A

HOTH Forecast & Estimates

7 analysts have analysed HOTH and the average price target is 5.1 USD. This implies a price increase of 436.84% is expected in the next year compared to the current price of 0.95.


Analysts
Analysts82.86
Price Target5.1 (436.84%)
EPS Next Y60.12%
Revenue Next YearN/A

HOTH Ownership

Ownership
Inst Owners8.61%
Ins Owners3.57%
Short Float %2.15%
Short Ratio0.83

HOTH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.54987.61B
JNJ JOHNSON & JOHNSON20.46574.955B
MRK MERCK & CO. INC.21.65292.01B
PFE PFIZER INC9.19153.798B
BMY BRISTOL-MYERS SQUIBB CO10123.713B
ZTS ZOETIS INC18.6656.1B
RPRX ROYALTY PHARMA PLC- CL A8.5225.427B
VTRS VIATRIS INC6.3117.921B
ELAN ELANCO ANIMAL HEALTH INC24.512.337B
AXSM AXSOME THERAPEUTICS INC225.049.236B

About HOTH

Company Profile

HOTH logo image Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Company Info

HOTH THERAPEUTICS INC

1177 Avenue Of The Americas, 5Th Floor Suite 5066

New York City NEW YORK 10020 US

CEO: Robb Knie

Employees: 2

HOTH Company Website

HOTH Investor Relations

Phone: 16467562997

HOTH THERAPEUTICS INC / HOTH FAQ

What does HOTH do?

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).


What is the stock price of HOTH THERAPEUTICS INC today?

The current stock price of HOTH is 0.95 USD. The price increased by 10.68% in the last trading session.


What is the dividend status of HOTH THERAPEUTICS INC?

HOTH does not pay a dividend.


What is the ChartMill rating of HOTH THERAPEUTICS INC stock?

HOTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of HOTH THERAPEUTICS INC (HOTH)?

HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).


How many employees does HOTH THERAPEUTICS INC have?

HOTH THERAPEUTICS INC (HOTH) currently has 2 employees.